|
Press Releases |
|
|
|
Monday, January 18, 2021 |
|
SinoMab Dosed First Healthy Subject in Phase I Clinical Trial of SN1011 in China |
SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the first healthy subject was successfully dosed in the Phase I clinical trial of SN1011 more info >> |
|
Monday, November 23, 2020 |
|
SinoMab Commenced Construction of its China Headquarters |
SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Thursday, July 23, 2020 |
|
SinoMab entered into Strategic Collaboration with D2M |
SinoMab BioScience Limited ("SinoMab" of the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Wednesday, June 10, 2020 |
|
SinoMab Announces Clinical Results on its First-in-target SM03 at EULAR 2020 Congress |
SinoMab BioScience Limited ("SinoMab" or the "Company", stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases more info >> |
|
Friday, January 10, 2020 |
|
SinoMab Granted the "Most Popular Newly Listed Company" Award |
SinoMab BioScience Limited ("SinoMab" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce that the Group has won the title of the "Most Popular Newly Listed Company" at the 4th Hong Kong Golden Stocks Awards held in Shenzhen. more info >> |
|
Wednesday, November 20, 2019 |
|
Great Potential in RA Therapeutic Market, Sinomab Announces Latest Progress of its Drug Candidate SM03 Phase III Clinical Trial for the Treatment RA |
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases, is pleased to announce its latest progress of SM03 phase III clinical trial for the treatment rheumatoid arthritis. more info >> |
|
Wednesday, October 30, 2019 |
|
SinoMab BioScience Announces Proposed Listing on the Main Board of SEHK |
SinoMab BioScience Limited ("SinoMab BioScience" or the "Company", together with its subsidiaries, the "Group"; stock code: 3681.HK), a Hong Kong-based biopharmaceutical company dedicated to the research, development more info >> |
|
|
|
|
|
|
|
|
|
Latest Press Releases |
|
Over 80,000 international buyers at HKTDC's first three trade fairs in 2025
Jan 9, 2025 22:45 HKT/SGT
|
|
|
Education & Careers Expo opens next Thursday
Jan 9, 2025 22:40 HKT/SGT
|
|
|
Strengthening Supply Chains for a Sustainable Future
Jan 9, 2025 22:30 HKT/SGT
|
|
|
'Think Business, Think Hong Kong' opened doors to more fruitful, sustainable Hong Kong-Indonesia partnership
Jan 9, 2025 22:20 HKT/SGT
|
|
|
Where is the next Chinese drug that will make MNCs compete to grab orders?
Jan 9, 2025 21:34 HKT/SGT
|
|
|
CONTIOCEAN OFFICIALLY LISTED ON THE MAIN BOARD OF THE HONG KONG STOCK EXCHANGE
Jan 9, 2025 19:56 HKT/SGT
|
|
|
Stableton, Swiss Leader in VC Direct Secondaries, Partners with Alta to Expand Access to Global High-Growth Pre-IPO Investments
Jan 9, 2025 15:30 HKT/SGT
|
|
|
Ho Chi Minh to Host Asia's Longest Running Sustainability Event - The 17th Annual Global CSR & ESG Summit and Awards 2025
Jan 9, 2025 15:17 HKT/SGT
|
|
|
Sparkline Hosts Exclusive Webinar on Leveraging Google Analytics 4 for E-Commerce Success
Jan 9, 2025 13:00 HKT/SGT
|
|
|
China Medical System (00867) Obtained New Drug ZUNVEYL for the Treatment of Mild-to-Moderate Dementia of the Alzheimer's Type
Jan 9, 2025 08:00 HKT/SGT
|
|
|
Biotech Startups Get a Boost: ZAGENO and Hatch.Bio Labs Partner to Streamline Lab Operations
Jan 8, 2025 22:30 HKT/SGT
|
|
|
'Behind the Canvas Series 1: Jean-Michel Basquiat' Makes Its Global Debut in Singapore
Jan 8, 2025 17:00 HKT/SGT
|
|
|
Honda Presents World Premiere of Honda 0 Saloon and Honda 0 SUV Prototypes at CES 2025
Jan 8, 2025 17:32 JST
|
|
|
Honda and Renesas Sign Agreement to Develop High-Performance SoC for Software-Defined Vehicles
Jan 8, 2025 12:30 JST
|
|
|
The Quantum Revolution. How Quantum Computing Will Transform the Global Economy in the Next Decade
Jan 8, 2025 08:30 HKT/SGT
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|